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The physicochemical deposition of calcium-phosphate in the arterial wall is prevented
by calcification inhibitors. Studies in cohorts of patients with rare genetic diseases
have shed light on the consequences of loss-of-function mutations for different
calcification inhibitors, and genetic targeting of these pathways in mice have
generated a clearer picture on the mechanisms involved. For example, generalized
arterial calcification of infancy (GACI) is caused by mutations in the enzyme ecto-
nucleotide pyrophosphatase/phosphodiesterase-1 (eNPP1), preventing the hydrolysis
of ATP into pyrophosphate (PP). The importance of PP for inhibiting arterial
calcification has been reinforced by the protective effects of PP in various mouse
models displaying ectopic calcifications. Besides PP, Matrix Gla Protein (MGP) has
been shown to be another potent calcification inhibitor as Keutel patients carrying a
mutation in the encoding gene or -deficient mice develop spontaneous calcification of
the arterial media. Whereas PP and MGP represent locally produced calcification
inhibitors, also systemic factors contribute to protection against arterial calcification.
One such example is Fetuin-A, which is mainly produced in the liver and which forms
calciprotein particles (CPPs), inhibiting growth of calcium-phosphate crystals in the
blood and thereby preventing their soft tissue deposition. Other calcification
inhibitors with potential importance for arterial calcification include osteoprotegerin,
osteopontin, and klotho. The aim of the present review is to outline the latest insights
into how different calcification inhibitors prevent arterial calcification both under
physiological conditions and in the case of disturbed calcium-phosphate balance, and







Titre abrégé Front Cardiovasc Med
Identifiant
























Publié sur Okina (http://okina.univ-angers.fr)
